{
 "name": "捷立康",
 "slug": "tw-7686",
 "aliases": [
  "捷立康生物科技股份有限公司",
  "A-TOP",
  "7686"
 ],
 "ticker": "7686",
 "industry": "生技醫療業",
 "website": "https://www.a-top.tw/",
 "summary": "捷立康（7686）是興櫃的生技醫療類股公司，2021 年成立，2026 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "捷立康生物科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "A-TOP",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2026-08-31",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2021-07-29",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "曾昱嘉",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "曾昱嘉",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 501100000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "安永聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://www.a-top.tw/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：LipS-000（Volléa波麗雅）",
   "value": "胸部軟組織填補｜動物試驗進行中｜澳洲（規劃臨床）",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://a-top.tw/docs/investors/shareholders/earnings-call-2026-08-25.pdf",
   "note": "第43頁產品進度；第47頁澳洲臨床與TFDA時程為公司規劃。未揭露地區不推定上市地區。"
  },
  {
   "claim": "管線：LipS-001",
   "value": "身體部位脂肪組織填補｜動物試驗進行中｜未揭露",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://a-top.tw/docs/investors/shareholders/earnings-call-2026-08-25.pdf",
   "note": "第43頁產品進度；第47頁澳洲臨床與TFDA時程為公司規劃。未揭露地區不推定上市地區。"
  },
  {
   "claim": "管線：HeB-001（Jouvence-01柔緹絲）",
   "value": "臉部拉提｜動物試驗於2026年第二季完成；規劃TFDA送件｜台灣",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://a-top.tw/docs/investors/shareholders/earnings-call-2026-08-25.pdf",
   "note": "第43頁產品進度；第47頁澳洲臨床與TFDA時程為公司規劃。未揭露地區不推定上市地區。"
  },
  {
   "claim": "管線：HeB-002（Jouvence-02）",
   "value": "身體傷口縫合／軟組織拉提｜動物試驗進行中｜台灣（規劃TFDA送件）",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://a-top.tw/docs/investors/shareholders/earnings-call-2026-08-25.pdf",
   "note": "第43頁產品進度；第47頁澳洲臨床與TFDA時程為公司規劃。未揭露地區不推定上市地區。"
  },
  {
   "claim": "管線：Prisme（Face Analysis 3D System）",
   "value": "影像分析／量測／術前規劃與臨床決策輔助｜原型開發於2026年第三季完成；持續優化演算法｜未揭露",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://a-top.tw/docs/investors/shareholders/earnings-call-2026-08-25.pdf",
   "note": "第43頁產品進度；第47頁澳洲臨床與TFDA時程為公司規劃。未揭露地區不推定上市地區。"
  },
  {
   "claim": "催化劑：HeB-001（JOUVENCE）",
   "value": "TFDA取證（公司規劃）｜2027-Q1｜已公告",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://a-top.tw/docs/investors/shareholders/earnings-call-2026-08-25.pdf",
   "note": "第47頁法規列；未當成已核准。"
  },
  {
   "claim": "催化劑：HeB-001（JOUVENCE）",
   "value": "美國510(k)送件（公司規劃）｜2027（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://a-top.tw/docs/investors/shareholders/earnings-call-2026-08-25.pdf",
   "note": "第47頁法規圖表點位接近季度交界；保留可確認的2027年，不推定單一季度。"
  },
  {
   "claim": "催化劑：HeB-001（JOUVENCE）",
   "value": "美國510(k)取證（公司規劃）｜2027-Q4｜已公告",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://a-top.tw/docs/investors/shareholders/earnings-call-2026-08-25.pdf",
   "note": "第47頁法規列，非FDA承諾日。"
  },
  {
   "claim": "催化劑：LipS-000（Volléa）",
   "value": "臨床試驗啟動（公司規劃）｜2028-Q1｜已公告",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://a-top.tw/docs/investors/shareholders/earnings-call-2026-08-25.pdf",
   "note": "第43頁寫民國117年第一季；第47頁列澳洲HREC/IRB、CTN與首位收案時程，未把動物試驗當人體試驗。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-7686.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}